Monopolizing Baldness?

Pharmacia & Upjohn Inc. asked a judge Thursday to shut out generic competitors to its non-prescription Rogaine baldness drug, saying it met federal rules that allow a monopoly for three years.

The drug maker was stunned earlier this month when the Food and Drug Administration refused to grant that privilege and began approving generic versions of the treatment, known as minoxidil.

If allowed, the generic drugs are likely to be significantly cheaper than Rogaine’s $30 per month pricetag.